Israeli Firm to Commence Clinical Trial Testing Orally Administered COVID-19 Vaccine

Israeli Firm to Commence Clinical Trial Testing Orally Administered COVID-19 Vaccine

An Israeli biotech has developed an investigational, proprietary protein oral delivery (POD™) technology in the development of oral vaccines that are now only available via an imposing injection. Called Oravax, the parent company Oramed reports that the exclusive owner of a virus-like particle (VLP) vaccine technology that targets three SARS-CoV-2 virus surface proteins, including proteins less susceptible to mutation, making the vaccine potentially more effective against current and future variants of the COVID-19 virus. The VLP vaccine has been in the preclinical research process against COVID-19 variants, including the Delta variant. Oravax’s VLP vaccine technology is purportedly highly scalable with a low cost of goods and easily transferable.

The Clinical Trial

Now Oravax, again part of Oramed, gears up to commence clinical trials for its oral COVID-19 vaccine, first in Israel and then in additional clinical trial sites around the world. The study protocol has been approved by the Institutional Review Board (IRB) at Ichilov Hospital in Tel Aviv, Israel, and is now pending approval from the Israeli Ministry of Health.   Additionally, the company has commenced GMP manufac...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee